Response to comments on: Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
We thank Zheng et al for their interest in our recent study (1, 2). First, our and others' study did not identify identical TDF-resistant mutants. Firstly, more mutations were need to hurdle higher genetic barrier. HBV is easy to develop resistant mutation for LAM with low genetic barrier, all LAM resistant mutants contain mutation of rtM204. Whereas for high genetic barrier inhibitor ETV, resistance was mostly developed in three site combination mutations.